Detalles de la búsqueda
1.
Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients.
Br J Haematol
; 194(2): 393-402, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34195988
2.
Evolving characteristics and outcome of secondary acute promyelocytic leukemia (APL): A prospective analysis by the French-Belgian-Swiss APL group.
Cancer
; 121(14): 2393-9, 2015 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25845577
3.
Azacitidine in untreated acute myeloid leukemia: a report on 149 patients.
Am J Hematol
; 89(4): 410-6, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24375487
4.
Repurposing the Bis-Biguanide Alexidine in Combination with Tyrosine Kinase Inhibitors to Eliminate Leukemic Stem/Progenitor Cells in Chronic Myeloid Leukemia.
Cancers (Basel)
; 15(3)2023 Feb 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36765952
5.
Measurement of imatinib uptake by flow cytometry.
Cytometry A
; 81(11): 996-1004, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22930640
6.
Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience.
Blood
; 115(9): 1690-6, 2010 Mar 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-20018913
7.
Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?
Haematologica
; 101(7): e280-3, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27056923
8.
Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Lancet Oncol
; 11(11): 1029-35, 2010 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-20965785
9.
Efficiency of nilotinib to target chronic phase-chronic myeloid leukaemia primary mature CD34- and immature CD34+ cells.
Sci Rep
; 11(1): 6187, 2021 03 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-33731863
10.
Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?
Blood
; 122(13): 2286-8, 2013 Sep 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-24072851
11.
Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies.
Haematologica
; 95(6): 892-9, 2010 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-20015890
12.
Additional prognostic impact of the percentage of erythroid cells in the bone marrow of patients with myelodysplastic syndromes.
Leuk Res
; 77: 8-13, 2019 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-30605856
13.
Clinical impact of genetic alterations including germline DDX41 mutations in MDS/low-blast count AML patients treated with azacitidine-based regimens.
Leukemia
; 38(4): 918-922, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38368440
14.
Aryl hydrocarbon receptor (AHR) is a novel druggable pathway controlling malignant progenitor proliferation in chronic myeloid leukemia (CML).
PLoS One
; 13(8): e0200923, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30091999
15.
Long-term follow-up of autologous stem cell transplantation after intensive chemotherapy in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Haematologica
; 91(3): 373-6, 2006 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-16531261
16.
Phosphorylation of spleen tyrosine kinase at tyrosine 348 (pSyk³48) may be a marker of advanced phase of Chronic Myeloid Leukemia (CML).
Leuk Res
; 39(3): 329-34, 2015 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-25612940
17.
Outcome of acute promyelocytic leukemia (APL) in children and adolescents: an analysis in two consecutive trials of the European APL Group.
J Clin Oncol
; 30(14): 1641-6, 2012 May 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-22473162
18.
Pegylated IFN-α2a combined to imatinib mesylate 600mg daily can induce complete cytogenetic and molecular responses in a subset of chronic phase CML patients refractory to IFN alone or to imatinib 600mg daily alone.
Leuk Res
; 35(1): 80-6, 2011 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-20605207
19.
Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Leuk Res
; 35(11): 1444-8, 2011 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-21715006
20.
Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: a report on 62 cases.
Leuk Res
; 35(7): 863-7, 2011 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-21396711